The global hunger for groundbreaking weight loss drugs has spurred a booming industry of counterfeit medications available on the black market, with potent drugs like retatrutide, still in clinical trials, being widely sold online.
Users seeking rapid weight loss or management of conditions such as polyendocrine metabolic ovarian syndrome (PMOS) are turning to these unverified substances. Lisa King, who has been taking a counterfeit version of retatrutide since July, reported losing approximately 3kg (6lb) per week while also dieting and exercising. She believes it has helped regulate her menstrual cycle and increase her energy levels, while also potentially aiding PMOS symptoms like sugar cravings. However, she acknowledges the risks, stating she would stop immediately if negative side effects occurred.
Other individuals consuming counterfeit retatrutide have reported adverse effects including brain fog, nausea, diarrhea, loss of libido, and emotional numbness. Healthcare professionals are expressing growing concern over these reported side effects. Dr. Sahira Dar, a general practitioner and chair of the British Islamic Medical Association, emphasized the importance of healthcare providers inquiring about black market product use without judgment to encourage patient disclosure.
Pharmaceutical giant Eli Lilly, which has been developing retatrutide for nearly a decade, is actively combating the illegal sales. The company has initiated legal action against peptide suppliers, influencers, compounding pharmacies, and wellness clinics involved in manufacturing and marketing the fake medications. Eli Lilly reports it has flagged over 14,000 websites, advertisements, and social media posts for illegally marketing the drug and collaborates with law enforcement and regulatory bodies to curb illicit trade. A spokesperson cautioned that any retatrutide found online is unapproved, unverified, and carries significant risks.
Regulatory agencies are also taking action. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has conducted raids and seized numerous products falsely claiming to contain retatrutide. Efforts are underway to disrupt the illegal importation and distribution channels into the UK, though sales persist.
Despite the dangers of these black market drugs, experts like Professor O'Shea highlight that the underlying class of medications, GLP-1s, represents a significant advancement in managing obesity and understanding appetite regulation. He stressed the importance of distinguishing the legitimate therapeutic potential of these drugs from the risks associated with illicit versions.
Retatrutide is still undergoing clinical trials and has a considerable path to regulatory approval. Eli Lilly plans to submit its application to the U.S. Food and Drug Administration (FDA) in early 2025. The FDA review process can take up to a year, meaning the drug might not be legally available in the U.S. until late 2027 at the earliest. In the UK, market availability, pending MHRA approval, is anticipated around 2028.